Stocks › RPRX

Royalty Pharma plc

RPRX·Nasdaq·United States United States·USD
$68.45
+0.73 (+1.08%)
Close · Nov 20, 2026 · Close Prices from Tiingo.com
RPRX
Royalty Pharma plc · Nasdaq
Nasdaq 100S&P 500
Filings
Default90D1Y5YALL
RPRXS&P 500 (rebased)
Congress BuyCongress SellInsider BuyInsider SellForm 1448-K ResultsLobbying
Loading price history…
Daily closes, adjusted for splits and dividends · Close Prices from Tiingo.comHover a marker, every one is a filing · move across the line for the crosshair

Congressional Trades

Recent trades of RPRX by members of U.S. Congress · 0 on record

No congressional trades in RPRX on record.

Whale Activity

Position changes in RPRX reported for 2026-09-30 by 753 institutional filers
Increased: 271New: 109Held: 82Decreased: 215Closed: 44No prior filing: 32
  • Increased271
  • New109
  • Held82
  • Decreased215
  • Closed44
  • No prior filing32
FilerSharesValueChange
MORGAN STANLEY41.1M$2.40Bdecreased
Capital International Investors33.9M$1.98Bdecreased
BlackRock, Inc.29.1M$1.70Bincreased
FMR LLC19.3M$1.13Bdecreased
PRICE T ROWE ASSOCIATES INC /MD/14.7M$858.6Mincreased
STATE STREET CORP13.0M$755.9Mincreased
Swedbank AB10.3M$598.8Mdecreased
BAILLIE GIFFORD & CO9.2M$534.1Mdecreased
Capital World Investors8.8M$511.0Mdecreased
GEODE CAPITAL MANAGEMENT, LLC8.5M$497.5Mincreased
Invesco Ltd.7.3M$426.2Mincreased
VICTORY CAPITAL MANAGEMENT INC6.3M$368.6Mincreased

Every 13F filer's complete reported book, every quarter since 2013-06-30. 13F itself excludes short positions, cash and most options.

Insider Trading

Net shares bought (+) or sold (−) on the open market by RPRX insiders, by quarter · Form 4
-1.0M-500.0K0500.0K1.0M2025 Q1: 02025 Q12025 Q2: 02025 Q22025 Q3: -33.5K2025 Q32025 Q4: -776.9K2025 Q42026 Q1: -587.1K2026 Q12026 Q2: -453.5K2026 Q22026 Q3: -224.2K2026 Q32026 Q4: -386.2K2026 Q4

Recent Insider Transactions

700 transactions on record · newest first
All insider activity →
InsiderTypeSharesPriceValueDate
Coyne Terrance P.EVP & CFO Sale −9,835 $68.30 $672K Nov 17, 2026 Form 4 ↗
Coyne Terrance P.EVP & CFO Sale −14.8K $68.30 $1.0M Nov 17, 2026 Form 4 ↗
Hite ChristopherEVP & Chairman, Partnering Sale −100.0K $68.15 $6.8M Nov 17, 2026 Form 4 ↗
Urist MarshallEVP, Research & Investments Sale −23.6K $69.47 $1.6M Nov 16, 2026 Form 4 ↗
Urist MarshallEVP, Research & Investments Sale −1,408 $69.99 $99K Nov 16, 2026 Form 4 ↗
Coyne Terrance P.EVP & CFO Sale −90.2K $68.87 $6.2M Nov 16, 2026 Form 4 ↗
Coyne Terrance P.EVP & CFO Sale −7,122 $68.87 $490K Nov 16, 2026 Form 4 ↗
Coyne Terrance P.EVP & CFO Sale −135.2K $68.87 $9.3M Nov 16, 2026 Form 4 ↗
Urist MarshallEVP, Research & Investments Sale −4,126 $57.10 $236K Oct 5, 2026 Form 4 ↗
Bassler Bonnie LDirector Grant / award +642 $58.41 $37K Sep 30, 2026 Form 4 ↗
Urist MarshallEVP, Research & Investments Sale −4,126 $57.88 $239K Sep 28, 2026 Form 4 ↗
Hite ChristopherEVP & Chairman, Partnering Sale −3,927 $58.93 $231K Sep 22, 2026 Form 4 ↗
Hite ChristopherEVP & Chairman, Partnering Sale −96.1K $58.51 $5.6M Sep 22, 2026 Form 4 ↗
Hite ChristopherEVP & Chairman, Partnering Gift −16.8K $0.00 $0 Aug 19, 2026 Form 4 ↗
Hite ChristopherEVP & Chairman, Partnering Sale −100.0K $59.97 $6.0M Aug 18, 2026 Form 4 ↗
Coyne Terrance P.EVP & CFO Sale −1,772 $59.14 $105K Aug 13, 2026 Form 4 ↗
Coyne Terrance P.EVP & CFO Sale −9,230 $58.59 $541K Aug 13, 2026 Form 4 ↗
Urist MarshallEVP, Research & Investments Grant / award +8,252 $0.00 $0 Aug 5, 2026 Form 4 ↗
Coyne Terrance P.EVP & CFO Grant / award +11.0K $0.00 $0 Aug 5, 2026 Form 4 ↗
Hite ChristopherEVP & Chairman, Partnering Grant / award +11.0K $0.00 $0 Aug 5, 2026 Form 4 ↗

Fund Holders

Mutual funds and ETFs holding RPRX · SEC Form N-PORT
FundSharesValue% of fundAs of
VANGUARD EXTENDED MARKET INDEX FUND
VANGUARD INDEX FUNDS
4.5M$250.7M0.26%Jun 30, 2026
VictoryShares Free Cash Flow ETF
Victory Portfolios II
2.4M$136.7M1.76%Jun 30, 2026
Invesco Discovery Mid Cap Growth Fund
AIM Investment Funds (Invesco Investment Funds)
1.7M$99.8M1.47%Jul 31, 2026
VANGUARD HIGH DIVIDEND YIELD INDEX FUND
VANGUARD WHITEHALL FUNDS
1.7M$97.3M0.10%Jul 31, 2026
iShares Russell 1000 Value ETF
iShares Trust
925.9K$51.9M0.07%Jun 30, 2026
VANGUARD GLOBAL EQUITY FUND
VANGUARD HORIZON FUNDS
925.0K$51.9M0.68%Jun 30, 2026
iShares U.S. Pharmaceuticals ETF
iShares Trust
880.1K$49.3M4.33%Jun 30, 2026
Eventide Dividend Opportunities Fund
MUTUAL FUND SERIES TRUST
774.1K$43.4M3.05%Jun 30, 2026
iShares MSCI USA Momentum Factor ETF
iShares Trust
653.9K$38.2M0.15%Jul 31, 2026
Invesco Health Care Fund
AIM Investment Funds (Invesco Investment Funds)
441.0K$25.8M2.13%Jul 31, 2026

Mutual funds and ETFs whose N-PORT filings list RPRX's shares (CUSIP G7709Q104), each fund at its latest report since Apr 21, 2026, largest positions first. Bonds, options and short positions are left out.

Activist & Passive Stakes

Schedule 13D / 13G beneficial-ownership filings
  • Abigail P. JohnsonSCHEDULE 13G/A · passive (13G) · 19.3M shares4.3%
    Nov 5, 2026 · ↗
  • FMR LLCSCHEDULE 13G/A · passive (13G) · 19.3M shares4.3%
    Nov 5, 2026 · ↗
  • Legorreta Investments, LLCSCHEDULE 13D/A · activist (13D) · 37.5M shares7.8%
    Aug 17, 2026 · ↗
  • Legorreta G. PabloSCHEDULE 13D/A · activist (13D) · 101.8M shares18.7%
    Aug 17, 2026 · ↗
  • Severgnini Achille G.SCHEDULE 13D/A · activist (13D) · 21.4M shares4.8%
    Jun 16, 2026 · ↗
  • Butterfield Fiduciary Administrators Trust Company LimitedSCHEDULE 13D/A · activist (13D) · 21.4M shares4.8%
    Jun 16, 2026 · ↗
  • Capital International InvestorsSCHEDULE 13G/A · passive (13G) · 37.8M shares8.8%
    May 14, 2026 · ↗
  • Morgan Stanley Investment Management Inc.SCHEDULE 13G/A · passive (13G) · 35.9M shares8.5%
    Aug 5, 2025 · ↗
  • Morgan StanleySCHEDULE 13G/A · passive (13G) · 38.9M shares9.2%
    Aug 5, 2025 · ↗

Corporate Lobbying

Estimated quarterly lobbying spending reported under the LDA, filings naming Royalty Pharma plc as client

No lobbying filings found naming Royalty Pharma plc as the client.

Government Contracts

Federal awards to Royalty Pharma plc · USAspending

No federal contract awards found for Royalty Pharma plc.

U.S. Patents

Recent USPTO applications naming Royalty Pharma plc

No USPTO patent applications found for Royalty Pharma plc.

Annual Financials

From RPRX's 10-K filings · XBRL
Fiscal yearFY2025FY2024FY2023FY2022FY2021
Revenue$2.38B$2.26B$2.35B$2.24B$2.29B
Operating income$1.56B$1.29B$1.49B$307.1M$1.43B
Net income$770.9M$859.0M$1.13B$42.8M$619.7M
Diluted EPS$1.78$1.91$2.53$0.10$1.49
Operating cash flow$2.49B$2.77B$2.99B$2.14B$2.02B
Cash and equivalents$618.7M$929.0M$477.0M$1.71B$1.54B
Total assets$19.62B$18.22B$16.38B$16.81B$17.52B
Total liabilities$9.91B$7.88B$6.30B$7.29B$7.27B

As Royalty Pharma plc tagged them in its 10-K filings: totals for the year on the income and cash-flow lines, values at the year's end on the balance-sheet lines. Latest 10-K, filed Feb 11, 2026 ↗

Stock Splits

Every split and reverse split in the price history

No stock splits in RPRX's price history.

Material Events (8-K)

Corporate events filed with the SEC
  • 8-K · Items 2.02, 9.01Results of operationsNov 4, 2026
    EDGAR ↗
  • 8-K · Items 2.02, 9.01Results of operationsAug 5, 2026
    EDGAR ↗
  • 8-K · Items 5.07Shareholder voteJun 4, 2026
    EDGAR ↗
  • 8-K · Items 1.01, 2.03, 9.01Material agreement · Direct financial obligationMay 28, 2026
    EDGAR ↗
  • 8-K · Items 2.02, 9.01Results of operationsMay 6, 2026
    EDGAR ↗
  • 8-K · Items 1.01, 5.03, 9.01Material agreement · Bylaw amendmentDec 31, 2024
    EDGAR ↗

About Royalty Pharma plc

From SEC EDGAR company records
Industry (SIC 2834)Pharmaceutical Preparations
SectorHealthcare
HeadquartersNEW YORK, NY
IncorporatedX0